Etanercept Patient Assistance Program: Another Data Source for Epidemiological Studies?
|Brian C Chan1, Soo Jin Seung1, David McLean2, Mary Bell3, Neil H Shear4 and Nicole Mittmann1*|
|1Health Outcomes and PharmacoEconomics (HOPE) Research Centre, Division of Clinical Pharmacology, Sunnybrook Health Sciences Centre, Canada|
|2Adjuva, A Division of World Travel Protection Canada Inc|
|3Division of Rheumatology, Department of Medicine, Sunnybrook Health Sciences Centre, Canada|
|4Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, Canada|
|*Corresponding Author :||Nicole Mittmann
HOPE ResearchCentre, Scientist
Sunnybrook Health Sciences Centre, Assistant Professor
Department of Pharmacology, University of Toronto
2075 Bayview Avenue, E240
Toronto, Ontario M4N 3M5, Canada
Tel: 416-480-6100 ext. 1652
E-mail: [email protected]
|Received March 20, 2013; Accepted April 25, 2013; Published April 29, 2013|
|Citation: Chan BC, Seung SJ, McLean D, Bell M, Shear NH, et al. (2013) Etanercept Patient Assistance Program: Another Data Source for Epidemiological Studies? Adv Pharmacoepidem Drug Safety 2:132. doi:10.4172/2167-1052.1000132|
|Copyright: © 2013 Chan BC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
Background: Patient assistance programs (PAP) have been established for biologic disease modifying therapies such as etanercept to improve patient knowledge and compliance and provide a means for follow-up. The information collected through these programs is a potential data source to determine patient characteristics, patient outcomes, treatment adherence and reimbursement practices of individuals prescribed biologic disease modifying therapies.
Objective: To describe the population enrolled in the Enliven® Services Patient Assistance Program and to determine one-year retention rates.
Methods: A retrospective review of a Canadian cohort of patients enrolled in an etanercept PAP diagnosed with rheumatoid arthritis (RA) was conducted. Demographic and utilization information was collected for all subjects enrolled in the period between 2000 and 2007. One-year retention rates were also calculated from the data collected. Descriptive statistics were used to characterize the data.
Results: 14,335 subjects prescribed etanercept were enrolled in Enliven®. Average age at time of enrollment was 53 years. Three-quarters of subjects were female and four-fifths were English speaking. The largest percentage
Conclusion: The analysis provides a snapshot of individuals administered etanercept therapy over a 7-year timeframe. PAPs are a valuable source of data for research on biological therapies in addition to the support provided to the patients.